Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:ZBIO

Zenas BioPharma Q1 2026 Earnings Report

Zenas BioPharma logo
$20.83 +0.07 (+0.34%)
Closing price 04:00 PM Eastern
Extended Trading
$21.20 +0.38 (+1.80%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Zenas BioPharma EPS Results

Actual EPS
N/A
Consensus EPS
-$1.37
Beat/Miss
N/A
One Year Ago EPS
N/A

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$25.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zenas BioPharma Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
12:30PM ET

Conference Call Resources

Zenas BioPharma Earnings Headlines

Leon Moulder, Jr. Purchases 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock
May 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30751650
Leon Moulder, Jr. Buys 35,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock
May 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30751680
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
May 6 at 1:00 AM  |  InvestorPlace (Ad)
Zenas BioPharma rises as CEO continues insider purchases
April 30, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/zenas-biopharma-rises-as-ceo-continues-insider-purchases/ar-AA226bXF
Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026
April 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4896887-zenas-strong-buy-on-obexelimab-enhancement-and-expected-sle-data-q4-2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 17, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1036034638
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies. Its integrated research infrastructure encompasses medicinal chemistry, in vitro and in vivo pharmacology, as well as manufacturing capabilities to support rapid progression of lead molecules into clinical development.

The company’s pipeline includes immuno-oncology candidates designed to modulate checkpoint pathways in solid tumors, alongside antiviral programs targeting broad-spectrum viral threats. Each program is engineered to combine high specificity with favorable pharmacokinetic properties, with key assets currently in IND-enabling stages and early clinical trials.

To advance its programs, Zenas BioPharma collaborates with academic institutions and contract research organizations, leveraging external expertise and resources. Serving global markets, the company is committed to addressing unmet medical needs and bringing differentiated therapies to patients worldwide.

View Zenas BioPharma Profile
Earnings Tools